You are here

Antibody-Membrane Switch (AMS) technology for optimized antibody engineering

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43AI109982-01A1
Agency Tracking Number: R43AI109982
Amount: $224,310.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NIAID
Solicitation Number: PA13-234
Timeline
Solicitation Year: 2014
Award Year: 2014
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
1230 BORDEAUX DRIVE
SUNNYVALE, CA 94089-1202
United States
DUNS: 556962439
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 JAMES LARRICK
 (415) 264-6311
 jwlarrick@gmail.com
Business Contact
 ERIC HOANG
Phone: (408) 747-5201
Email: ops@pano.com
Research Institution
 Stub
Abstract

Abstract Generation of high productivity cell lines remains a major bottleneck in therapeutic antibody engineering. To address this need, we have developed a proprietary Antibody-Membrane Switch (AMS) technology that facilitates rapid cloning of cell lines for commercial production of antibodies. This technology streamlines identification of high-productivity clones, shaving at least 6-8 months off timelines using conventional cell culture techniques employing gene amplification methodology. More importantly, AMS technology permits assessment of multiple critical cell line attributes besides productivity in an early stage, greatly simplifying downstream process development. Preliminary studies demonstrate reduction to practice of the underlying AMS methods.In Phase I, AMS will be optimized using two biosimilar antibodies. In Phase II, the optimized methods will be extended to antibody library screening. AMS technology permits the discovery of antibodies to be seamlessly linked to downstream cell line develo

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government